LÓPEZ JARAMILLO, JOSÉ PATRICIO

Preferred name

Main Affiliation

Facultad de Ciencias de la Salud Eugenio Espejo

CENIEC - Grupo de Investigación de Enfermedades Crónicas

Web Site

Google Scholar

ORCID

0000-0002-9122-8742

Scopus Author ID

7004478068

Now showing 1 - 10 of 36

Some of the metrics are blocked by your
consent settings
Reevaluating nutrition as a risk factor for cardio-metabolic diseases
(Universidad del Valle, 2018-06-29)
LOPEZ JARAMILLO, JOSÉ PATRICIO
;
Johanna Otero
;
Paul Anthony Camacho
;
Manuel Baldeón
;
Marco Fornasini
<jats:p>Introduction: The consumption of saturated fats is considered a risk factor for cardiovascular diseases. Objective: Review published papers on the role of macro-nutrient intake in cardiovascular risk. Results: Recent reports from the PURE study and several previous metaanalyses, show that the consumption of total saturated and unsaturated fat is not associated with risk of acute myocardial infarction or mortality due to cardiovascular disease. High carbohydrate intake was associated with the highest risk of total and cardiovascular mortality, while total fat consumption or of its different types was associated with a lower risk of mortality. A high consumption of fruits, vegetables and legumes was associated with lower risk of total mortality and non-cardiovascular mortality. The consumption of 100 g of legumes, two or three times a week, ameliorated deficiencies of the nutrients contained in these foods and was associated with a reduction in the risk of developing chronic noncommunicable diseases. Conclusion: A healthy diet should be balanced and varied, be composed of a proportion of complex carbohydrates rich in fibber between 50-55% of the daily energy consumed, of saturated and unsaturated fat (25-30%), animal and vegetable protein (including legumes) between 15-25%, vitamins, minerals and water. These nutrients are abundantly present in fruits, vegetables, cereals, legumes, milk and its derivatives, eggs and meats, so public policies should promote the availability and access to these nutrients within primary prevention programs to reduce the growing prevalence of cardio-metabolic diseases.</jats:p>
Some of the metrics are blocked by your
consent settings
Pharmacological Treatment of Hypertension: Effects in Endothelial Function
(Bentham Science Publishers Ltd., 2018-08)
Leonardo Cobos-Segarra
;
LOPEZ JARAMILLO, JOSÉ PATRICIO
;
Carlos Ponte-Negretti CI
;
Raul Villar
;
Ernesto Penaherrera
<jats:sec> <jats:title /> <jats:p>The vascular endothelium plays an important role to maintain the functional integrity of the cardiovascular system. The synthesis and secretion of substances with biological activity such as prostacyclin and NO give endothelium the vasodilator, antithrombotic, and antiatherosclerotic properties. Endothelial dysfunction participates in the genesis of HTA, but also hypertension produces endothelial damage. The major class of antihypertensive drugs has beneficial effects in the recuperation of the endothelial function, actions that are contributing to explain the impact of the adequate control of HTA in the reduction of CV events.</jats:p> </jats:sec>
Some of the metrics are blocked by your
consent settings
La realidad del riesgo cardiovascular en Iberoamérica
(Elsevier BV, 2020-10)
LOPEZ JARAMILLO, JOSÉ PATRICIO
;
José López-López
;
Salim Yusuf
Some of the metrics are blocked by your
consent settings
The positive impact of the Life's Essential 8 in the prevention of incident heart failure
(Oxford University Press (OUP), 2025-02-08)
LOPEZ JARAMILLO, JOSÉ PATRICIO
;
LOPEZ FLECHER, MAVEL ESTEFANIA
;
Jose P Lopez-Lopez
Heart failure (HF) prevalence is increasing rapidly, particularly in middle- and low-income countries, contributing to considerable treatment costs and weakening their health systems.1 Individually, cardiovascular risk factors are associated with a higher risk of developing HF. For example, the NHANES I study reported that smoking is an independent risk factor for incident HF, apart from coronary artery disease (population attributable fraction = 17%).2 A recent meta-analysis showed that hypertension is associated with a 71% increase in the risk of HF and that a 20 mmHg increase in systolic blood pressure is associated with a 28% increase in HF risk.3 Similarly, a pooled analysis of 61 prospective studies on blood pressure and mortality from HF reported a hazard ratio (HR) of 0.53 [95% confidence interval (CI): 0.48–0.59] for a 20 mmHg lower systolic blood pressure.4 However, few studies have examined the combination and the effect of the trajectory, the burden of lifestyles, and the control of risk factors in large observational studies.
Some of the metrics are blocked by your
consent settings
Manejo de los pacientes con diabetes en la época de COVID-19: Recomendaciones prácticas
(Saber CDCH-UCV, 2020-08-10)
José López López
;
LOPEZ JARAMILLO, JOSÉ PATRICIO
<jats:p>La nueva enfermedad COVID-19 es causada por el beta coronavirus SARS-CoV-2. Los primeros casos de neumonía grave se registraron en China a finales de diciembre de 2019. La enfermedad se ha expandido rápidamente en todo el mundo y tiene un amplio espectro de manifestaciones clínicas, desde sujetos asintomáticos hasta pacientes que desarrollan enfermedad multisistémica grave y muerte. Se ha demostrado que la hipertensión y la diabetes son más frecuentes en las personas con COVID-19 y que la presencia de diabetes se asocia con mayor severidad de la enfermedad y peores desenlaces. En el presente artículo revisamos los posibles mecanismos por los cuales los pacientes diabéticos tienen un mayor riesgo para presentar mayor mortalidad por COVID-19 y sugerimos acciones preventivas que deben ser seguidas por la población en general y particularmente por los pacientes diabéticos.</jats:p>
Some of the metrics are blocked by your
consent settings
Survey of knowledge for diagnosing and managing prediabetes in Latin-America: cross-sectional study
(Springer Science and Business Media LLC, 2019-12)
Jennifer Garay
;
Paul A. Camacho
;
Jose Lopez-Lopez
;
Juliana Alvernia
;
Marcela Garcia
<jats:title>Abstract</jats:title><jats:sec> <jats:title>Background</jats:title> <jats:p>Prediabetes has been proposed as a risk factor for the development of type 2 diabetes mellitus (DM2) and cardiovascular disease (CVD). Despite the clinical importance of prediabetes, little is known about the level of knowledge, beliefs and barriers to screening and treating prediabetes amongst care health providers in Latin America. The aim of the present survey was to evaluate the knowledge and beliefs about prediabetes amongst in Latin American health care providers.</jats:p> </jats:sec><jats:sec> <jats:title>Methodology</jats:title> <jats:p>In a cross-sectional study, we adapted the written survey designed by the Johns Hopkins University group, and applied it to health care providers across Latin America during three meetings, in 2017, and with physicians from primary care centers in Bucaramanga, Colombia convened in 2017. The survey consisted of questions under four headings, diabetes screening, management of prediabetes, pharmacological treatment—metformin use, and demographic information. We perform a descriptive analysis to determine the differences in responses between different medical specialties.</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>The majority of the care providers that answered the survey were Colombian physicians, 54.5% of respondents had 10 years or more since completing their training and more women responded. Only 9.5% identified the 12 prediabetes risk factors described in the literature. The most common risk factor identified was a family history of diabetes, followed by overweight, a sedentary lifestyle and dyslipidemia, while ethnicity was the risk factor least commonly. 47.1% answered that laboratory tests to detect prediabetes are fasting glucose and HbA1C, 82.5% correctly identified fasting plasma glucose as the best test, 35.9% correctly responded that to the recommended weight loss goal is 5 to 7% and 49.1% that 150 min is considered the minimum level of physical activity per week. 78% agreed that the identification and treatment of prediabetes is important. 56% believed that patients with prediabetes progress more rapidly to diabetes and 40.6% considered that metformin could reduce the risk of diabetes in patients already diagnosed with prediabetes.</jats:p> </jats:sec><jats:sec> <jats:title>Conclusion</jats:title> <jats:p>These results demonstrate that there are important gaps in the knowledge of the diagnosis, clinical implications and management of prediabetes amongst Latin America health providers.</jats:p> </jats:sec>
Some of the metrics are blocked by your
consent settings
Core outcome sets for trials of interventions to prevent and to treat multimorbidity in adults in low and middle-income countries: the COSMOS study
(BMJ, 2024-08)
Aishwarya Lakshmi Vidyasagaran
;
Rubab Ayesha
;
Jan R Boehnke
;
Jamie Kirkham
;
Louise Rose
Introduction The burden of multimorbidity is recognised increasingly in low- and middle-income countries (LMICs), creating a strong emphasis on the need for effective evidence-based interventions. Core outcome sets (COS) appropriate for the study of multimorbidity in LMICs do not presently exist. These are required to standardise reporting and contribute to a consistent and cohesive evidence-base to inform policy and practice. We describe the development of two COS for intervention trials aimed at preventing and treating multimorbidity in adults in LMICs. Methods To generate a comprehensive list of relevant prevention and treatment outcomes, we conducted a systematic review and qualitative interviews with people with multimorbidity and their caregivers living in LMICs. We then used a modified two-round Delphi process to identify outcomes most important to four stakeholder groups (people with multimorbidity/caregivers, multimorbidity researchers, healthcare professionals and policymakers) with representation from 33 countries. Consensus meetings were used to reach agreement on the two final COS. Registration: https://www.comet-initiative.org/Studies/Details/1580. Results The systematic review and qualitative interviews identified 24 outcomes for prevention and 49 for treatment of multimorbidity. An additional 12 prevention and 6 treatment outcomes were added from Delphi round 1. Delphi round 2 surveys were completed by 95 of 132 round 1 participants (72.0%) for prevention and 95 of 133 (71.4%) participants for treatment outcomes. Consensus meetings agreed four outcomes for the prevention COS: (1) adverse events, (2) development of new comorbidity, (3) health risk behaviour and (4) quality of life; and four for the treatment COS: (1) adherence to treatment, (2) adverse events, (3) out-of-pocket expenditure and (4) quality of life. Conclusion Following established guidelines, we developed two COS for trials of interventions for multimorbidity prevention and treatment, specific to adults in LMIC contexts. We recommend their inclusion in future trials to meaningfully advance the field of multimorbidity research in LMICs. PROSPERO registration number CRD42020197293.
Some of the metrics are blocked by your
consent settings
Single-pill combination therapy is the standard of care for hypertension, but it is time for the next step: Implementation
(Elsevier BV, 2024-12)
Jose P. Lopez-Lopez
;
LOPEZ JARAMILLO, JOSÉ PATRICIO
The GMRx2 trial1 in adults with high blood pressure (BP) demonstrated that after 12 weeks, a low-dose single-pill combination of telmisartan, amlodipine, and indapamide significantly reduced BP levels compared to several dual combinations (telmisartan with amlodipine, telmisartan with indapamide, or amlodipine with indapamide). Adverse events did not differ between the groups. This novel therapeutic option could improve high BP control
Some of the metrics are blocked by your
consent settings
Secondary Prevention Medications in 17 Countries Grouped by Income Level - PURE : A Prospective Cohort Study
(Elsevier BV, 2025-02)
Philip Joseph
;
Alvaro Avezum
;
Chinthanie Ramasundarahettige
;
Prem K. Mony
;
Rita Yusuf
Background: It is unclear whether global use of medications for secondary cardiovascular (CVD) prevention is improving over time. Objectives: This study across 17 high-, middle- and low-income countries described variations in secondary CVD prevention medication use over a median follow-up of 12 years. Methods: In the multinational PURE (Prospective Urban Rural Epidemiology) cohort study, we conducted a repeated cross-sectional analysis to examine temporal variations in the use of secondary prevention medications in participants with CVD. In participants with coronary artery disease, we focused on antiplatelet agents, statins, renin-angiotensin system (RAS) inhibitors, and β-blockers. In participants with stroke, we focused on antiplatelet agents, statins, RAS inhibitors, and other blood pressure–lowering drugs. Medications were collected at baseline and on 4 subsequent follow-up visits. Results: The analysis included 7,409 participants with a diagnosis of CVD at the baseline visit, 8,792 at the second visit, 9,236 at the third visit, 11,082 at the fourth visit, and 11,677 at the last visit. The median age at baseline was 58.0 years, and 52.9% of the participants were female. The median follow-up was 12 years, with the median year of the baseline visit in 2007 and the fifth visit in 2019. Over this period, use of 1 or more classes of medications for secondary CVD prevention was 41.3% (95% CI: 40.2%-42.4%) at baseline, peaked at 43.1% (95% CI: 42.0%-44.1%), and then decreased to 31.3% (95% CI: 30.4%-32.1%) by the last study visit. In high-income countries, this use decreased from 88.8% (95% CI: 86.6%-91.0%) to 77.3% (95% CI: 74.9%-79.6%). In upper-middle-income countries, this use increased from 55.0% (95% CI: 52.8%-57.3%) to 61.1% (95% CI: 59.1%-63.1%). In lower-middle-income countries, use of at least 1 class of medications was 29.5% (95% CI: 28.1%-30.9%) at baseline, peaked at 31.7% (95% CI: 30.4%-33.1%), and then decreased to 13.4% (95% CI: 12.5%-14.2%) by the last visit. In low-income countries, use of at least 1 class of medications was 20.8% (95% CI: 18.1%-23.5%) at baseline, peaked at 47.3% (95% CI: 44.8%-49.9%), and then decreased to 27.5% (95% CI: 25.2%-29.9%) by the last study visit. Conclusions: Globally and in most country income-level groups, the use of medications for secondary CVD prevention has been low, with little improvement over time.
Some of the metrics are blocked by your
consent settings
Guidelines on the management of arterial hypertension and related comorbidities in Latin America
(Ovid Technologies (Wolters Kluwer Health), 2017-08)
Barbosa, Eduardo
;
Coca, Antonio
;
LOPEZ JARAMILLO, JOSÉ PATRICIO
;
Ramirez, Agustín J.
;
Sanchez, Ramiro A.

LÓPEZ JARAMILLO, JOSÉ PATRICIO

Filters

Settings

Sort By

Results per page